publication . Article . Other literature type . 2019

Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis

Nedogoda, S. V.; Salasyuk, A. S.; Barykina, I. N.; Smirnova, V. O.;
Open Access
  • Published: 01 Oct 2019 Journal: Oncohematology, volume 14, pages 98-108 (issn: 1818-8346, eissn: 2413-4023, Copyright policy)
  • Publisher: Publishing House ABV Press
<jats:p><jats:bold>Objective: </jats:bold>to assess the economic outcomes of using anidulafungin (Eraxis®) in comparison with the recommended treatment regimens in adult patients with invasive candidiasis.</jats:p><jats:p><jats:bold>Materials and methods. </jats:bold>The economic impact assessment was carried out using “cost–effectiveness” analysis and “budget impact” analysis. “Cost–effectiveness” and “budget impact” analyses were performed in Microsoft Excel model.</jats:p><jats:p><jats:bold>Results. </jats:bold>An analysis of the effectiveness showed that the use of anidulafungin is characterized by higher survival (79.25 % vs 66.17 % for caspofungin and 60.8...
Persistent Identifiers
Medical Subject Headings: bacterial infections and mycoses
free text keywords: candidiasis, caspofungin, micafungin, “budget impact” analysis, “cost–effectiveness” analysis, Medicine, business.industry, business, Invasive candidiasis, medicine.disease, Internal medicine, medicine.medical_specialty, Anidulafungin, medicine.drug, Adult patients, lcsh:Diseases of the blood and blood-forming organs, lcsh:RC633-647.5
Any information missing or wrong?Report an Issue